Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on February 17, 2022 (the “2021 Form 10-K”). As used in this Quarterly Report, the terms “Pediatrix”, the “Company”, “we”, “us” and “our” refer to the parent company, Pediatrix Medical Group, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, “PMG”), together with PMG’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (“affiliated professional contractors”). Certain subsidiaries of PMG have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company’s 2021 Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.
Company Name Change
On July 1, 2022, effective after the close of the market, we changed our corporate name from "Mednax, Inc." to “Pediatrix Medical Group, Inc." signifying our return to our core focus in caring for women, babies and children. Our common stock continues to trade on the New York Stock Exchange under the ticker symbol “MD.”
Overview
Pediatrix is a leading provider of physician services including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 38 states and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (“NICUs”), to babies born prematurely or with medical complications; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology, pediatric urology services and pediatric primary and urgent care.
Coronavirus Pandemic ("COVID-19")
COVID-19 has had an impact on the demand for medical services provided by our affiliated clinicians. Beginning in mid-March 2020 and continuing throughout the second quarter of 2020, our operating results were significantly impacted by COVID-19, but volumes began to normalize in mid-2020 and substantially recovered throughout 2020 with no material impacts from COVID-19 or its variants in 2021 or thus far in 2022. However, due to the continued uncertainties surrounding the timeline of and impacts from COVID-19 and with multiple variant strains still circulating, we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time.
CARES Act
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing financial aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to COVID-19. The Department of Health and Human Services (“HHS”) is administering this program, and our affiliated physician practices within continuing operations received an aggregate of $11.1 million and $7.7 million during the six months ended June 30, 2022 and 2021, respectively.
General Economic Conditions and Other Factors
Our operations and performance depend significantly on economic conditions. During the three months ended June 30, 2022, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (“GHC Programs”) increased as compared to the three months ended June 30, 2021. We could experience additional shifts toward GHC Programs if changes occur in economic behaviors or population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance or if there are additional impacts from COVID-19 or its variants. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, costs of managed care premiums and patient responsibility amounts continue to rise, and accordingly, we may experience lower net revenue resulting from increased bad debt due to patients’ inability to pay for certain services.
Healthcare Reform
The Patient Protection and Affordable Care Act (the “ACA”) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal
13
Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion.
Despite the ACA going into effect over a decade ago, continuous legal and Congressional challenges to the law’s provisions and persisting uncertainty with respect to the scope and effect of certain provisions have made compliance costly. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Congress may again attempt to enact substantial or target changes to the ACA in the future. Additionally, Centers for Medicare & Medicaid Services (“CMS”) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future.
At the end of 2017, Congress repealed the part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty, known as the individual mandate. In light of these changes, in December 2018, a federal district court in Texas declared that key portions of the ACA were inconsistent with the U.S. Constitution and that the entire ACA is invalid as a result. Several states appealed this decision, and in December 2019, a federal court of appeals upheld the district court’s conclusion that part of the ACA is unconstitutional but remanded for further evaluation whether in light of this defect the entire ACA must be invalidated. Democratic attorneys general and the House appealed the Fifth Circuit’s decision to the Supreme Court. On March 2, 2020, the Supreme Court agreed to hear the case, styled California v. Texas, during the 2020-21 term. Oral arguments took place on November 2, 2020 and on June 17, 2021, the Court held that the plaintiffs lacked standing to challenge the ACA. Notwithstanding the Supreme Court's ruling, we cannot say for certain whether there will be future challenges to the ACA or what impact, if any, such challenges may have on our business. Changes resulting from these proceedings could have a material impact on our business.
In late 2020 and early 2021, the results of the federal and state elections changed which persons and parties occupy the Office of the President of the United States and the U.S. Senate and many states’ governors and legislatures. The current Administration may propose sweeping changes to the U.S. healthcare system, including expanding government-funded health insurance options, additional Medicaid expansion or replacing current healthcare financing mechanisms with systems that would be entirely administered by the federal government. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.
In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid or Medicaid payment rates set forth under state law. Historically, Congress and the Administration have sought to convert Medicaid into a block grant or to institute per capita spending caps, among other things. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. Many states have recently shifted a majority or all of their Medicaid program beneficiaries into Managed Medicaid Plans. Managed Medicaid Plans have some flexibility to set rates for providers, but many states require minimum provider rates in their contracts with such plans. In July of each year, CMS releases the annual Medicaid Managed Care Rate Development Guide which provides federal baseline rules for setting reimbursement rates in managed care plans. We could be affected by lower reimbursement rates in some of all of the Managed Medicaid Plans with which we participate. We could also be materially impacted if we are dropped from the provider network in one or more of the Managed Medicaid Plans with which we currently participate.
We cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.
Medicaid Expansion
The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state’s historic eligibility levels to 133% of the federal poverty level. To date, 38 states and the District of Columbia have expanded Medicaid eligibility to cover this additional low-income patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level. Recently, Democrats in Congress have sought to expand Medicaid or Medicaid-like coverage in states that have not yet expanded Medicaid. They also have sought to reduce payments to certain hospitals in some of these states. Additionally, as noted above, Congress is currently considering altering the terms and state remuneration for Medicaid expansion pursuant to the ACA. Should any of these changes take effect, we cannot predict with any assurance the ultimate effect to reimbursements for our services.
“Surprise” Billing Legislation
In late 2020, Congress enacted legislation intended to protect patients from “surprise” medical bills when services are furnished by providers who are not subject to contractual arrangements and payment limitations with the patient’s insurer. Effective January 1, 2022, patients will be protected from unexpected or “surprise” medical bills that could arise from out-of-network emergency care provided at an out-of-network facility or at in-network facilities by out-of-network providers and out-of-network nonemergency care provided at in-network facilities without the patient’s informed consent. Many states have passed similar legislation, but the federal government has been working to enact a ban on surprise billing for quite some time that pertains to ERISA health insurance plans that are not addressed under state legislation.
14
Under the “No Surprises Act" ("NSA"), patients are only required to pay the in-network cost-sharing amount, which has been determined through an established regulatory formula and will count toward the patient’s health plan deductible and out-of-pocket cost-sharing limits. Providers will generally not be permitted to balance bill patients beyond this cost-sharing amount. An out-of-network provider will only be permitted to bill a patient more than the in-network cost-sharing amount for care if the provider gives the patient notice of the provider’s network status and delivers to the patient or their health plan an estimate of charges within certain specified timeframes, and obtains the patient’s written consent prior to the delivery of care. Providers that violate these surprise billing prohibitions may be subject to state enforcement action or federal civil monetary penalties. Out of network providers can pursue recourse through an independent dispute resolution ("IDR") process to determine payment amounts for out of network services. These IDR results will bind both the provider and payor for a 90-day period. The final rules implementing the NSA are currently being reviewed by the Department of Health and Human Services, Department of Labor and Department of Treasury. In addition, certain IDR-related provisions of the NSA Interim Final Rules are being challenged in courts by many provider groups, and the result of this litigation may alter the NSA Interim Final Rules and the final rules that are expected to be published later in 2022. Accordingly, we cannot predict how these IDR results will compare to the rates that our affiliated physicians customarily receive for their services.
These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient’s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Moreover, these measures could affect our ability to contract with certain payors and under historically similar terms and may cause, and the prospect of these changes may have caused, payors to terminate their contracts with us and our affiliated practices, further affecting our business, financial condition, results of operations, cash flows and the trading price of our securities.
Non-GAAP Measures
In our analysis of our results of operations, we use certain non-GAAP financial measures. We report adjusted earnings before interest, taxes and depreciation and amortization from continuing operations, which is defined as income (loss) from continuing operations before interest, income taxes, depreciation and amortization, and transformational and restructuring related expenses. We also report adjusted earnings per share (“Adjusted EPS”) from continuing operations which consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense, transformational and restructuring related expenses and any impacts from discrete tax events. For the three and six months ended June 30, 2022 and 2021, both Adjusted EBITDA and Adjusted EPS are being further adjusted to exclude the impacts from the loss on the early extinguishment of debt and the gain on sale of a building for relevant periods.
We believe these measures, in addition to income (loss) from continuing operations, net income (loss) and diluted net income (loss) from continuing operations per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.
For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and six months ended June 30, 2022 and 2021, refer to the tables below (in thousands, except per share data).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Income from continuing operations attributable to Pediatrix Medical Group, Inc. |
|
$ |
30,701 |
|
|
$ |
30,533 |
|
|
$ |
9,760 |
|
|
$ |
35,885 |
|
Interest expense |
|
|
8,409 |
|
|
|
16,879 |
|
|
|
20,227 |
|
|
|
34,524 |
|
Gain on sale of building |
|
|
— |
|
|
|
(7,280 |
) |
|
|
— |
|
|
|
(7,280 |
) |
Loss on early extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
57,016 |
|
|
|
14,532 |
|
Income tax provision |
|
|
12,332 |
|
|
|
7,363 |
|
|
|
4,931 |
|
|
|
2,408 |
|
Depreciation and amortization expense |
|
|
8,775 |
|
|
|
8,106 |
|
|
|
17,544 |
|
|
|
16,137 |
|
Transformational and restructuring related expenses |
|
|
5,338 |
|
|
|
9,932 |
|
|
|
6,759 |
|
|
|
14,810 |
|
Adjusted EBITDA from continuing operations attributable to
Pediatrix Medical Group, Inc. |
|
$ |
65,555 |
|
|
$ |
65,533 |
|
|
$ |
116,237 |
|
|
$ |
111,016 |
|
15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
|
2022 |
|
|
2021 |
|
Weighted average diluted shares outstanding |
|
85,619 |
|
|
85,933 |
|
Income from continuing operations and diluted income from
continuing operations per share attributable to Pediatrix Medical Group, Inc. |
|
$ |
30,701 |
|
|
$ |
0.36 |
|
|
$ |
30,533 |
|
|
$ |
0.36 |
|
Adjustments (1): |
|
|
|
|
|
|
|
|
|
|
|
|
Amortization (net of tax of $541 and $576) |
|
|
1,624 |
|
|
|
0.02 |
|
|
|
1,728 |
|
|
|
0.02 |
|
Stock-based compensation (net of tax of $1,084 and $1,434) |
|
|
3,252 |
|
|
|
0.04 |
|
|
|
4,301 |
|
|
|
0.04 |
|
Transformational and restructuring expenses (net of tax of
$1,335 and $2,483) |
|
|
4,003 |
|
|
|
0.05 |
|
|
|
7,449 |
|
|
|
0.09 |
|
Gain on sale of building (net of tax of $1,820) |
|
|
— |
|
|
|
— |
|
|
|
(5,460 |
) |
|
|
(0.06 |
) |
Net impact from discrete tax events |
|
|
294 |
|
|
|
— |
|
|
|
(3,516 |
) |
|
|
(0.04 |
) |
Adjusted income and diluted EPS from continuing operations
attributable to Pediatrix Medical Group, Inc. |
|
$ |
39,874 |
|
|
$ |
0.47 |
|
|
$ |
35,035 |
|
|
$ |
0.41 |
|
(1)A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended June 30, 2022 and 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
June 30, |
|
|
|
2022 |
|
|
2021 |
|
Weighted average diluted shares outstanding |
|
85,914 |
|
|
85,653 |
|
Income from continuing operations and diluted income from
continuing operations per share attributable to Pediatrix Medical Group, Inc. |
|
$ |
9,760 |
|
|
$ |
0.11 |
|
|
$ |
35,885 |
|
|
$ |
0.42 |
|
Adjustments (1): |
|
|
|
|
|
|
|
|
|
|
|
|
Amortization (net of tax of $1,082 and $1,466) |
|
|
3,245 |
|
|
|
0.04 |
|
|
|
4,400 |
|
|
|
0.05 |
|
Stock-based compensation (net of tax of $2,193 and $2,363) |
|
|
6,578 |
|
|
|
0.07 |
|
|
|
7,089 |
|
|
|
0.08 |
|
Transformational and restructuring expenses (net of tax of
$1,690 and $3,702) |
|
|
5,069 |
|
|
|
0.06 |
|
|
|
11,108 |
|
|
|
0.13 |
|
Gain on sale of building (net of tax of $1,820) |
|
|
— |
|
|
|
— |
|
|
|
(5,460 |
) |
|
|
(0.06 |
) |
Loss on early extinguishment of debt (net of tax of $14,254 and $3,633) |
|
|
42,762 |
|
|
|
0.50 |
|
|
|
10,899 |
|
|
|
0.13 |
|
Net impact from discrete tax events |
|
|
786 |
|
|
|
0.01 |
|
|
|
(8,583 |
) |
|
|
(0.10 |
) |
Adjusted income and diluted EPS from continuing operations
attributable to Pediatrix Medical Group, Inc. |
|
$ |
68,200 |
|
|
$ |
0.79 |
|
|
$ |
55,338 |
|
|
$ |
0.65 |
|
(1)A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the six months ended June 30, 2022 and 2021.
Results of Operations
Three Months Ended June 30, 2022 as Compared to Three Months Ended June 30, 2021
Our net revenue attributable to continuing operations was $486.0 million for the three months ended June 30, 2022, as compared to $473.0 million for the same period in 2021. The increase in revenue of $13.0 million, or 2.8%, was primarily attributable to increases in revenue from net acquisitions, partially offset by a decrease in same-unit revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue decreased by $6.1 million, or 1.3%. The decrease in same-unit net revenue was comprised of a decrease of $8.6 million, or 1.9%, from net reimbursement-related factors, partially offset by an increase of $2.5 million, or 0.6%, related to patient service volumes. The net decrease in revenue related to net reimbursement-related factors was primarily due to a decrease in revenue resulting from an increase in the percentage of our patients being enrolled in GHC programs, as well as certain revenue cycle management transition activities, partially offset by increases in revenue from contract and administrative fees received from our hospital partners and CARES Act relief. The increase in revenue from patient service volumes was related to increases in neonatology and other services, partially offset by slight declines in maternal-fetal medicine and pediatric cardiology services.
Practice salaries and benefits attributable to continuing operations increased $13.8 million, or 4.3%, to $330.8 million for the three months ended June 30, 2022, as compared to $317.0 million for the same period in 2021. Of the $13.8 million increase, $21.4 million was related to salaries, driven by increases from acquisitions as well as in our existing units, partially offset by a decrease of $7.6 million related to benefits and incentive compensation, reflecting lower incentive compensation expense, partially offset by higher benefit costs attributable to the increase in salaries expense.
Practice supplies and other operating expenses attributable to continuing operations increased $5.6 million, or 23.4%, to $29.8 million for the three months ended June 30, 2022, as compared to $24.2 million for the same period in 2021. The increase was primarily attributable to practice supply, rent and other costs related to our existing units, including increases in information technology costs as compared to the prior year period.
16
General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our affiliated physician practices and services. General and administrative expenses were $61.2 million for the three months ended June 30, 2022, as compared to $71.0 million for the same period in 2021. The net decrease of $9.8 million is primarily related to lower professional fees, including legal fees, as well as a net savings in revenue cycle management expenses. General and administrative expenses as a percentage of net revenue was 12.6% for the three months ended June 30, 2022, as compared to 15.0% for the same period in 2021.
Gain on sale of building was $7.3 million for the three months ended June 30, 2021 and resulted from the sale of our secondary corporate office building.
Transformational and restructuring related expenses attributable to continuing operations were $5.3 million for the three months ended June 30, 2022, as compared to $9.9 million for the same period in 2021. The decrease of $4.6 million reflects reductions in consulting fees and contract termination costs during the second quarter of 2022 as compared to the prior year period, partially offset by an increase in position elimination costs.
Depreciation and amortization expense attributable to continuing operations was $8.8 million for the three months ended June 30, 2022, as compared to $8.1 million for the same period in 2021. The net increase of $0.7 million was primarily related to an increase in acquisition related depreciation and amortization expense.
Income from operations attributable to continuing operations increased $0.2 million, or 0.3%, to $50.2 million for the three months ended June 30, 2022, as compared to $50.0 million for the same period in 2021. Our operating margin was 10.3% for the three months ended June 30, 2022, as compared to 10.6% for the same period in 2021. The slight decrease in our operating margin was primarily due to net favorable impacts in our same-unit results from lower general and administrative expenses, partially offset by lower same-unit revenue and higher overall operating expenses. Excluding transformation and restructuring related expenses and gain on sale of building, our income from operations attributable to continuing operations was $55.5 million and $52.7 million, and our operating margin was 11.4% and 11.1% for the three months ended June 30, 2022 and 2021, respectively. We believe excluding the impacts from the transformational and restructuring related activity as well as the gain on sale of building provides a more comparable view of our operating income and operating margin from continuing operations.
Total non-operating expenses attributable to continuing operations were $7.1 million for the three months ended June 30, 2022, as compared to $12.1 million for the same period in 2021. The net increase in non-operating expenses was primarily related to a decrease in interest expense resulting from the redemption of our 6.25% senior unsecured notes due 2027 (the “2027 Notes”) in February 2022, partially offset by the interest expense related to the issuance of 5.375% senior unsecured notes due 2030 (the "2030 Notes") in February 2022 and a decrease in other income of $3.3 million, primarily related to the cessation of transition services provided to the buyers of our divested medical groups during 2021.
Our effective income tax rate attributable to continuing operations (“tax rate”) was 28.7% for the three months ended June 30, 2022 as compared to 19.4% for the three months ended June 30, 2021. The second quarter 2021 tax rate includes a net discrete tax benefit of $3.5 million, primarily related to a change in estimate for the 2020 net operating loss carryback as allowed under the CARES Act for refund at the 35% federal rate. Discrete tax impacts during the three months ended June 30, 2022 were nominal. After excluding discrete tax impacts during the three months ended June 30, 2021, our effective income tax rate was 28.7%. We believe excluding discrete tax impacts provides a more comparable view of our tax rate.
Income from continuing operations attributable to Pediatrix Medical Group, Inc. was $30.7 million for the three months ended June 30, 2022, as compared to $30.5 million for the same period in 2021. Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc. was $65.6 million for the three months ended June 30, 2022, as compared to $65.5 million for the same period in 2021.
Diluted income from continuing operations per common and common equivalent share attributable to Pediatrix Medical Group, Inc. was $0.36 on weighted average shares outstanding of 85.6 million for the three months ended June 30, 2022, as compared to diluted net income of $0.36 on weighted average shares outstanding of 85.9 million for the same period in 2021. Adjusted EPS from continuing operations was $0.47 for the three months ended June 30, 2022, as compared to $0.41 for the same period in 2021.
Loss from discontinued operations, net of tax, was $3.6 million for the three months ended June 30, 2022, as compared to income of $4.5 million for the same period in 2021. Diluted loss from discontinued operations per common and common equivalent share was $0.04 for the three months ended June 30, 2022, as compared to diluted net income of $0.05 for the three months ended June 30, 2021.
Net income attributable to Pediatrix Medical Group, Inc. was $27.1 million for the three months ended June 30, 2022, as compared to $35.0 million for the same period in 2021. Diluted net income per common and common equivalent share attributable to Pediatrix Medical Group, Inc. was $0.32 for the three months ended June 30, 2022, as compared to $0.41 for the same period in 2021.
Six Months Ended June 30, 2022 as Compared to Six Months Ended June 30, 2021
Our net revenue attributable to continuing operations was $968.3 million for the six months ended June 30, 2022, as compared to $919.7 million for the same period in 2021. The increase in revenue of $48.6 million, or 5.3%, was primarily attributable to increases in revenue from net acquisitions, partially offset by a decrease in same-unit revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue decreased by $2.8 million, or 0.3%. The decrease in same-unit
17
net revenue was comprised of a decrease of $20.4 million, or 2.3%, from net reimbursement-related factors, partially offset by an increase of $17.6 million, or 2.0%, related to patient service volumes. The net decrease in revenue related to net reimbursement-related factors was primarily due to a decrease in revenue related to certain revenue cycle management transition activities and a decrease in revenue resulting from an increase in the percentage of our patients being enrolled in GHC Programs, partially offset by increases in revenue from contract and administrative fees received from our hospital partners and CARES Act relief. The increase in revenue from patient service volumes was related to increases across all our hospital-based and office-based women’s and children’s services.
Practice salaries and benefits attributable to continuing operations increased $37.9 million, or 6.0%, to $673.9 million for the six months ended June 30, 2022, as compared to $636.0 million for the same period in 2021. Of the $37.9 million increase, $40.7 million was related to salaries, driven by increases from acquisitions as well as in our existing units, partially offset by a decrease of $2.8 million related to benefits and incentive compensation, reflecting lower incentive compensation expense, partially offset by an increase in benefit costs attributable to the increase in salaries expense.
Practice supplies and other operating expenses attributable to continuing operations increased $11.9 million, or 25.7%, to $58.3 million for the six months ended June 30, 2022, as compared to $46.4 million for the same period in 2021. The increase was primarily attributable to practice supply, rent and other costs related to our acquisitions.
General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the day-to-day operations of our physician practices and services. General and administrative expenses were $122.5 million for the six months ended June 30, 2022, as compared to $137.5 million for the same period in 2021. The net decrease of $15.0 million is primarily related to lower professional fees, including legal fees, as well as a net savings in revenue cycle management expenses. General and administrative expenses as a percentage of net revenue was 12.6% for the six months ended June 30, 2022, as compared to 15.0% for the same period in 2021.
Gain on sale of building was $7.3 million for the six months ended June 30, 2021 and resulted from the sale of our secondary corporate office building during the second quarter of 2021.
Transformational and restructuring related expenses attributable to continuing operations were $6.8 million for the six months ended June 30, 2022, as compared to $14.8 million for the same period in 2021. The decrease of $8.0 million reflects the reduction in the scope of external consulting activities in 2022 as well as lower contract termination costs with the expenses during the six months ended June 30, 2022 primarily for position eliminations.
Depreciation and amortization expense attributable to continuing operations was $17.5 million for the six months ended June 30, 2022, as compared to $16.1 million for the same period in 2021. The increase of $1.4 million was primarily related to an increase in depreciation expense related to information technology equipment, partially offset by lower amortization expenses related to intangible assets, both at our existing units.
Income from operations attributable to continuing operations increased $13.2 million, or 17.3%, to $89.3 million for the six months ended June 30, 2022, as compared to $76.1 million for the same period in 2021. Our operating margin was 9.2% for the six months ended June 30, 2022, as compared to 8.3% for the same period in 2021. The increase in our operating margin was primarily due to favorable general and administrative expenses, partially offset by lower same-unit revenue and net increases in overall operating expenses as well as favorable net impacts from acquisitions. Excluding the transformation and restructuring related expenses and gain on sale of building, our income from operations attributable to continuing operations was $96.0 million and $83.7 million, and our operating margin was 9.9% and 9.1% for the six months ended June 30, 2022 and 2021, respectively. We believe excluding the impacts from the transformational and restructuring related activity as well as the gain on sale of building provides a more comparable view of our operating income and operating margin from continuing operations.
Total non-operating expenses attributable to continuing operations were $74.6 million for the six months ended June 30, 2022, as compared to $37.8 million for the same period in 2021. The net increase in non-operating expenses was primarily related to increase of $42.5 million in loss on early extinguishment of debt from the redemption of our 2027 Notes in February 2022 as compared to the loss associated with the redemption of our 2023 Notes in January 2021. In addition, there was a decrease in other income of $8.4 million for the six months ended June 30, 2022, as compared to the same period in 2021, related to the transition services provided to the buyers of our divested medical groups in 2021. Overall, during the six months ended June 30, 2022, a net increase to non-operating expense of $50.9 million from the loss on early extinguishment of debt and lower other income was partially offset by a decrease of $14.3 million in interest expense related to the issuance of the 2030 Notes, as compared to the interest expense on the 2027 Notes.
Our effective income tax rate was 33.6% for the six months ended June 30, 2022 compared to 6.3% for the six months ended June 30, 2021. The tax rate for the six months ended June 30, 2021 includes a net discrete tax benefit of $8.6 million, primarily related to a change in estimate for the 2020 net operating loss carryback as allowed under the CARES Act for refund at the 35% federal tax rate. After excluding discrete tax impacts, during the six months ended June 30, 2022 and 2021, our tax rate was 28.2% and 28.7%, respectively. We believe excluding discrete tax impacts on our tax rate provides a more comparable view of our effective income tax rate.
Income from continuing operations attributable to Pediatrix Medical Group, Inc. was $9.8 million for the six months ended June 30, 2022, as compared to income of $35.9 million for the same period in 2021. Adjusted EBITDA from continuing operations was $116.2 million for the six months ended June 30, 2022, as compared to $111.0 million for the same period in 2021.
18
Diluted income from continuing operations per common and common equivalent share attributable to Pediatrix Medical Group, Inc. was $0.11 on weighted average shares outstanding of 85.9 million for the six months ended June 30, 2022, as compared to diluted income per share of $0.42 on weighted average shares outstanding of 85.7 million for the same period in 2021. Adjusted EPS from continuing operations was $0.79 for the six months ended June 30, 2022, as compared to $0.65 for the same period in 2021.
Loss from discontinued operations, net of tax, was $3.8 million for the six months ended June 30, 2022, as compared to income of $16.8 million for the same period in 2021. Diluted loss from discontinued operations per common and common equivalent share was $0.04 for the six months ended June 30, 2022, as compared to diluted income per share of $0.19 for the same period in 2021.
Net income attributable to Pediatrix Medical Group, Inc. was $5.9 million for the six months ended June 30, 2022, as compared to $52.7 million for the same period in 2021. Diluted net income per common and common equivalent share was $0.07 for the six months ended June 30, 2022, as compared to $0.61 for the same period in 2021.
Liquidity and Capital Resources
As of June 30, 2022, we had $14.1 million of cash and cash equivalents attributable to continuing operations as compared to $387.4 billion at December 31, 2021. Additionally, we had working capital attributable to continuing operations of $129.9 million at June 30, 2022, a decrease of $283.3 million from working capital of $413.2 million at December 31, 2021. The net decrease in working capital is primarily due to the redemption of the 2027 Notes in February 2022, partially offset by the issuance of the 2030 Notes also in February 2022.
Cash Flows from Continuing Operations
Cash (used in) provided by operating, investing and financing activities from continuing operations is summarized as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
June 30, |
|
|
|
2022 |
|
|
2021 |
|
Operating activities |
|
$ |
(8,334 |
) |
|
$ |
(28,484 |
) |
Investing activities |
|
|
(39,625 |
) |
|
|
1,375 |
|
Financing activities |
|
|
(318,603 |
) |
|
|
(760,810 |
) |
Operating Activities from Continuing Operations
During the six months ended June 30, 2022, our net cash used in operating activities for continuing operations was $8.3 million, compared to $28.5 million for the same period in 2021. The net decrease in cash used of $20.2 million was primarily due to increases in cash flow from income taxes, deferred income taxes, accounts receivable and other liabilities, partially offset by a decrease in cash flow due to changes in accounts payable and accrued expenses, primarily related to higher incentive compensation payments, and increases in cash used for prepaid expenses and other current assets.
During the six months ended June 30, 2022, cash flow from accounts receivable for continuing operations decreased by $16.0 million, as compared to $26.0 million for the same period in 2021. The increase in cash flow from accounts receivable for the six months ended June 30, 2022 as compared to the prior year period was primarily due to lower increases in ending accounts receivable balances at existing units, excluding accounts receivable related to discontinued operations.
Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 58.2 days at June 30, 2022 as compared to 55.2 days at December 31, 2021. The increase in our DSO primarily related to the timing of cash collections at our existing units.
Investing Activities from Continuing Operations
During the six months ended June 30, 2022, our net cash used in investing activities for continuing operations of $39.6 million consisted of acquisitions payments of $28.2 million and capital expenditures of $13.7 million, partially offset by net proceeds from maturities and sales of investments of $1.1 million.
Financing Activities from Continuing Operations
During the six months ended June 30, 2022, our net cash used in financing activities for continuing operations of $318.6 million primarily consisted of $1.05 billion related to the redemption of the 2027 Notes, including the call premium, payments for financing costs of $8.4 million and the repurchase of $65.6 million of our common stock, partially offset by $400.0 million in proceeds from the issuance of the 2030 Notes, $250.0 million from our new term loan and net borrowings on our revolving line of credit of $153.5 million.
Liquidity
On February 11, 2022, we issued $400.0 million of 5.375% unsecured senior notes due 2030 (the “2030 Notes”). We used the net proceeds from the issuance of the 2030 Notes, together with $100.0 million drawn under our Revolving Credit Line (as defined below), $250.0
19
million of Term A Loan (as defined below) and approximately $308.0 million of cash on hand, to redeem (the “Redemption”) the 2027 Notes, which had an outstanding principal balance of $1.0 billion, and to pay costs, fees and expenses associated with the Redemption and the Credit Agreement Amendment (as defined below).
Also in connection with the Redemption, we amended and restated the Credit Agreement (the “Credit Agreement Amendment”) concurrently with the issuance of the 2030 Notes. The Credit Agreement, as amended by the Credit Agreement Amendment (the “Amended Credit Agreement”), among other things, (i) refinanced the prior unsecured revolving credit facility with a $450.0 million unsecured revolving credit facility, including a $37.5 million sub-facility for the issuance of letters of credit (the “Revolving Credit Line”), and a new $250.0 million term A loan facility (“Term A Loan”) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders under the Amended Credit Agreement.
The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Amended Credit Agreement bear interest at (i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate ("SOFR") for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if we select a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line, based on our consolidated net leverage ratio.
The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest coverage ratio, a maximum consolidated total consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, we may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, we are in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.
During the six months ended June 30, 2022, in connection with the redemption of our 2027 Notes and the Credit Agreement Amendment, we recognized a loss on early extinguishment of debt of $57.0 million, which primarily included cash premiums on the 2027 Notes and accelerated amortization of deferred financing costs.
At June 30, 2022, we had an outstanding principal balance on the Amended Credit Agreement of $400.4 million, composed of $153.5 million under the Revolving Credit Line and $246.9 million under the Term A Loan. We had $296.5 million available on the Amended Credit Agreement at June 30, 2022.
At June 30, 2022, we had an outstanding principal balance of $400.0 million on the 2030 Notes. Our obligations under the 2030 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Amended Credit Agreement. Interest on the 2030 Notes accrues at the rate of 5.375% per annum, or $21.5 million, and is payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022.
The indenture under which the 2030 Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, we may be required to repurchase the 2030 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.
At June 30, 2022, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Amended Credit Agreement and the 2030 Notes. We believe we will be in compliance with these covenants throughout 2022.
We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June 30, 2022 was $300.6 million, of which $32.5 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $54.1 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.
20
We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form 10-Q.
Caution Concerning Forward-Looking Statements
Certain information included or incorporated by reference in this Quarterly Report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2021 Form 10-K, including the section entitled “Risk Factors.”
21